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Abstract
Objective: To evaluate the long-term results of aggressive treatment of HCC recurrence.
Methods: Two hundred and nine consecutive patients underwent hepatic resection for HCC in our hospital. Tumour recurrence was diag-
nosed in 97 (51%) of the 190 patients with curative resection. Sixteen underwent hepatic resection: two right hepatectomies, one three-
segmentectomy, one left hepatectomy, five two-segmentectomies, six segmental resections and one subsegmentectomy. Two patients
with metastasis in the spine were submitted to a vertebral body resection. Twenty-five patients were treated with percutaneous ethanol in-
jection or intra-arterial chemoembolization. Fifty-four patients with a poor performance status and liver function or multiple extra hepatic
recurrences did not receive any treatment.
Results: There were no operative deaths. The postoperative mortality rate was 5.5% (one patient). The cumulative overall survival after the
second resection was respectively 89%, 46% and 31% at 1, 3 and 5 years. There was a significant difference in survival between patients
treated with repeat resection and those submitted to a non-surgical or conservative treatment ( p < 0.0001). There were no differences in
operative deaths, postoperative mortality and morbidity between the first and second hepatic resection.
Conclusions: Aggressive management with combined resection or loco regional therapy for intrahepatic recurrence and resection of isolated
extra-hepatic recurrence may offer long-term survival in selected patients. Second liver resection for recurrence of HCC can be safely
performed.
 2006 Elsevier Ltd. All rights reserved.
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The treatment of choice for hepatocellular carcinoma
(HCC) is surgical resection. Unfortunately, long-term re-
sults of HCC resection have been disappointing because
the rate of postoperative HCC recurrence is high. The ma-
jority of patients develop intrahepatic recurrence and
a smaller proportion develop both intrahepatic and extrahe-
patic or very rarely only extrahepatic recurrences.1e7 This
high recurrence rate might be due to inadequate resection
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or the persistence of multicentric hepatocarcinogenesis
foci in the remnant liver. Recurrence caused by inadequate
resection or intrahepatic metastases could be prevented by
anatomical resection on the basis of vascular anatomy, pre-
vention of intraoperative bleeding or blood transfusion, and
by obtaining a fair surgical margin (>10 mm). Although
there is some indication that adjuvant radioactive intra-
arterial infusion might decrease the rate of recurrence due
to multicentric hepatocarcinogenesis, this has not yet
been confirmed.
Aggressive treatment of HCC recurrence after liver re-
section increases patients’ survival.6e8 Re-resection of intra-
hepatic recurrence or isolated extrahepatic recurrence may
be effective in prolonging survival.4,6e12 Most frequently,
patients are not suitable for surgery because of the multifo-
cality and location of the tumours and/or the degree of
cirrhosis. In these patients, new lesions can be treated by
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taneous tumour destruction with ethanol injection (PEI) or
percutaneous thermal ablation (radiofrequency).
The purpose of this study was to analyse the results of
the aggressive treatment of HCC recurrence after resection
of HCC in a series of 97 consecutive patients.
Patients and methods
Between June 1984 and March 2004, 209 patients under-
went hepatic resection for HCC in the Surgical Department
of Antoine-Be´cle`re Hospital. One hundred and ninety re-
sections were curative (the type of resection in these 190
patients is indicated in Table 1). Patients were followed
up with serum aFP measurement and ultrasonography in
the first month after hepatectomy and every 4 months there-
after. Suspected intrahepatic recurrence was confirmed us-
ing a computerized tomography (CT) scan and/or hepatic
angiography and/or percutaneous biopsy. A chest radio-
graph or CT scan was used to detect any concurrent extra-
hepatic recurrence.
Tumour recurrence was diagnosed in 97 patients (51%)
of the 190 patients with curative resection, 88 of whom
were men (91%) and 9 women (9%). The mean age of
the patients with recurrence was 60.3  10.8 years (range
17e83 years). The stage of chronic liver disease at the
time of recurrence was classified according to the Childe
Pugh score:13 it was A in 90 (92.8%) and B in 7 (7.2%).
Recurrence was discovered by ultrasonography during sur-
veillance in 95 patients and by a-fetoprotein (aFP) increase
in two. Recurrence was confirmed by tumour biopsy in
39 of them. In other patients it presented typical features
in the CT scan and/or an increase in blood aFP above
100 ng/ml.
Recurrence occurred only in the liver in 76 patients
(78.4%), in the liver and other organs in 19 patients
(19.6%) and only in another organ in two patients (2%).
In only nine of the patients with liver recurrence (9.5%)
was it located near the hepatic stump. In all other patients
it occurred far from the hepatic stump: multifocal in 58
and uninodular (or less than three nodules) in 28. Metasta-
ses in the lung/pleura, lung/adrenal gland, lymph node,
Table 1
Type of hepatectomy in 190 patients having undergone curative resection
of hepatocellular carcinoma between June 1984 and March 2004
Type of resection Number of patients (n ¼ 190)
Extended right hepatectomy 15
Extended left hepatectomy 6
Right hepatectomy 29
Left hepatectomy 12
Central hepatectomy 4
Left lateral lobectomy 18
Combined segmentectomy 25
Segmentectomy 47
Subsegmentectomy 34bone and skin were respectively 11 (6%), 1 (0.5%), 3
(1.6%), 5 (2.6%), and 1 (0.5%).
Repeat liver resection was considered the treatment of
choice for resectable recurrent tumours in the liver. Deter-
mination of resectability was based on the number and
site of the tumours, their pathological features, any concur-
rent extrahepatic recurrence, size of liver remnant, liver
function, and general status of the patients. Among the 28
patients with fewer than three recurrent nodules, 16
(57.2%) underwent hepatic resection. The type of repeat re-
section was dependent on the size, number and location of
liver recurrence, the type of the first liver resection and liver
function. Three patients underwent major liver resection
(two right hepatectomies and one left hepatectomy) and
13 patients underwent either segmental resection of one
(six patients), two (five patients) or three segments (one pa-
tient) or subsegmentectomy (one patient). In addition, two
patients with spinal metastases underwent a vertebral
body resection.
Eleven patients with a single nodular recurrence and an
atrophied liver remnant and/or poor liver function, and 14
patients with multiple diffuse lesions and good hepatic
function were treated respectively by PEI (n ¼ 11) or
TACE (n ¼ 14).
Fifty-four patients with a poor performance status and
liver function or multiple extrahepatic recurrences did not
receive any oncological treatment.
Statistical analysis
Results were expressed as mean (SD) and median
(range). To compare characteristics among groups, the Stu-
dent’s t or chi-square tests for nominal variables were used.
Overall and disease-free survivals were determined in
patients with curative first and second resections after
exclusion of patients’ postoperative mortality. To compare
characteristics among groups chi-square or Kruskale
Wallis tests were used. Disease-free survival was evaluated
in the group of patients who were discharged from the
hospital from the date of surgery to the time of recurrence.
Cumulative analysis of overall and disease-free survivals
was calculated by the KaplaneMeier method, and statisti-
cal comparisons were based on the log-rank test. All anal-
yses were performed using Stat View software (version 5.1)
for Macintosh computer (Apple Computer, Inc., Cupertino,
CA) and statistical significance was considered when p
values were 0.05.
Results
Characteristics of patients with tumour recurrence
undergoing surgical or non-surgical treatment or
conservative treatment
Table 2 summarizes the clinical and pathological fea-
tures of the 97 patients with HCC recurrence after hepatic
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than non-cirrhotic patients (6%, p < 0.001) and signifi-
cantly more patients with three nodules or less in the group
of patients with re-resection ( p < 0.002) than in the other
two groups. None of the patients submitted to surgical treat-
ment had more than three nodules. Two patients with spinal
metastases without hepatic recurrence had vertebral body
resection.
Mortality and morbidity of the patients undergoing
repeat liver resection and non-surgical treatment
There were no operative deaths during repeat resection.
Postoperative mortality was 6% (one patient) (Table 3).
There were postoperative complications in five patients
(28%) (Table 3): ascites in three, lung infection in one
and encephalopathy in one. There were no statistically sig-
nificant differences in postoperative mortality and morbid-
ity between the first and second hepatic resection (Table 3).
Table 2
Pretherapeutic characteristics of patients with hepatocellular carcinoma re-
currence treated by repeat resection, non-surgical treatment or conservative
treatments
Variables Repeat
resection
(n ¼ 16)
Non-surgical
treatment
(n ¼ 25)
Conservative
treatment
(n ¼ 54)
p
Age (years) 61.3  7.9 62.3  8.7 58.3  12.3 ns
Sex (male/female) 14/2 21/4 51/3 ns
ChildePugh score
B/A
1/15 1/24 4/50 ns
Cirrhosis present/
absent
15/1 10/15 50/4 0.001
First resection
major/minor
2/14 10/15 19/35 ns
Hepatic recurrence
Nodular 7 11 14
2e3 nodules 9 3 10
>3 nodules 0 11 30 0.002
Extrahepatic
recurrence
0 11 1 ns
Portal invasion
(yes/no)
1/15 2/23 7/47 ns
Tumour
differentiation
(well/
moderate þ poor)
9/7 10/15 21/33 ns
Table 3
Operative mortality and postoperative mortality and morbidity after first
(209 patients) and second (16 patients) hepatic resections
First hepatic
resection (n ¼ 209)
Second hepatic
resection (n ¼ 16)
p
Operative mortality (%) 0 (0) 0 (0) ns
Postoperative mortality (%) 16 (7.7) 1 (6) ns
Postoperative morbidity % 70 (34) 5 (28) nsOne patient (4%) died from hepatic necrosis after TACE.
Three other patients (12%) developed complications: asci-
tes in two and variceal bleeding in one. There was no mor-
tality and no complications in the 11 patients treated by
PEI.
Survival of patients with hepatic recurrence after
resection of HCC
Cumulative overall survival of the 97 patients with re-
current HCC from the time of resection was respectively
83%, 44%, and 22% at 1, 3, and 5 years The mean (SD)
and median overall survival was respectively 30.3
(23.7) months and 27 months (range 2e108). Cumulative
disease-free survival was respectively 55.3%, 18%, and 4.3%
at 1, 3, and 5 years The mean (SD) and median disease-
free survival were 15.9 (17) months and 12 months (range
1e100).
After HCC recurrence, the cumulative 1-, 3-, and 5-year
overall survival from the time of recurrence was respec-
tively 54%, 21.3% and 5% (Fig. 1) and the mean (SD)
and median disease-free survival were 15.8 (17.4) months
and 12 months (range 0e100).
Following repeat resection of tumour recurrence, the cu-
mulative overall 1-, 3- and 5-year survival was respectively
89%, 46% and 31% (Fig. 2) and the mean (SD) and median
survival were 49 (10) months and 27 months (range
8e100).
Following non-surgical treatment of tumour recurrence,
the cumulative overall 1-, 3-, and 5-year survival was re-
spectively 58%, 27% and 0% (Fig. 2) and the mean (SD)
and median survival were respectively 19 (3) months
and15 months (range 1e48).
In patients receiving non-specific treatment of HCC re-
currence, the cumulative overall 1-, 3-, and 5-year survival
was respectively 30.2%, 9.7% and 0% (Fig. 2) and the
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Figure 1. Overall cumulative survival rate after diagnostic and treatment of
97 patients with hepatocellular carcinoma recurrence.
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5 months (range 0e58).
Cumulative survival after tumour recurrence was signif-
icantly better in patients with repeat resection than in those
having non-surgical or conservative treatment ( p < 0.0001)
(Fig. 2). Furthermore, survival was significantly better
( p < 0.025) in patients having non-surgical treatment
than in those with conservative treatment. Median survival
was significantly higher in patients with repeat liver resec-
tion than in those with non-surgical treatment ( p < 0.001)
or those without specific treatment ( p < 0.001).
Recurrence and disease-free survival of the patients
undergoing repeat liver resection
Fourteen patients (87.5%) had another recurrence after
repeat liver resection. It was located within the liver in 12
(86%) and outside in 2 (14%). Disease-free survival after
second liver resection was respectively 40%, 13%, and
10.5% at 1, 3, and 5 years. Three of them (21.4%) had
a third liver resection (three segmentectomies) with no op-
erative mortality or morbidity. The mean (SD) and median
survival after a third liver resection was 12 (8) months and
11 months (range 1e24). Two other patients with liver re-
currence after repeat liver resection had intra-arterial che-
moembolization and one had PEI. The mean (SD) and
median survival of these patients was 6 (7.1) months and
6 months (range 4e21).
Treatment of extrahepatic metastases after
HCC resection
Two patients with metastasis in the lumbar spine sur-
vived 3 and 13 months after a vertebral body resection.
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Figure 2. Overall survival from the time recurrence of patients with surgi-
cal treatment (n ¼ 18; continuous line), non-surgical treatment (n ¼ 25,
dotted/continuous line) and conservative treatment (n ¼ 54, dotted line).
The difference between the cumulative survival of patients with surgical
treatment and those having a non-surgical or a conservative treatment is
significant ( p < 0.0001). The difference between patients having non-
surgical treatment and those having conservative treatment is significant
( p < 0.025).One developed a secondary recurrence in the liver and
the other in the lung.
Discussion
There have been few reports on the results of the treat-
ment of HCC recurrence after resection.4,6e12,14,15 Our
study emphasizes several important points: first, an aggres-
sive policy with surgical or non-surgical treatments im-
proved survival in patients with HCC recurrence; second,
re-resection of recurrent HCC whenever possible offered
the best chances of cure; and finally, re-resection could
be performed safely even in patients with cirrhosis.
Recurrence of HCC after resection
A high recurrence rate (ranging from 50% to 60%) re-
mains the major drawback after resection of HCC.1e7,16,17
and is responsible for low long-term survival. In our series
the intrahepatic recurrence rate was 51% after curative
resection of a HCC. In 81% of our patients the major cause
of late deaths was malignant cachexia resulting from tu-
mour recurrence. Our study confirms that HCC recurrence
most often takes place in the liver and is mainly located
far from the liver stump. This high recurrence rate after
liver resection may result either from the growth of occult
carcinomatous foci in the liver remnant, from the ongoing
carcinogenic process associated with chronic liver disease
or from an inadequate margin.
Prevention of HCC after resection
It is difficult to decrease this high recurrence rate: previ-
ous studies on postoperative adjuvant chemotherapy after
hepatic resection for HCC have equally failed to demon-
strate a reduction,18 and this has been confirmed at our cen-
tre (unpublished data). However, studies of hepatic arterial
administration of I131 radiolabelled oil (lipiocis)19e21 have
shown promising results in reducing the HCC recurrence
rate. Other approaches such as interferon-alpha therapy
after resection of hepatitis C virus-related HCC22,23 and
immunotherapeutic strategies with activation of an HCC-
specific response24e27 are still under evaluation, although
these new adjuvant therapies require further evaluation by
more randomized studies. We are now engaged in a French
multicentric trial in adjuvant therapy with lipiocis follow-
ing HCC resection. In the initial group of 190 patients
with a curative resection, 53 (28%) were within Milan cri-
teria and could have been treated by liver transplantation
rather than liver resection. Whether or not liver transplanta-
tion should be offered as the primary treatment for small
hepatocellular carcinoma or should be reserved as salvage
treatment in case of recurrence is still being debated.17,28,29
It is worth noting that four of the patients undergoing repeat
resection for recurrence also had Milan criteria for
transplantation.
750 J.G. Tralh~ao et al. / EJSO 33 (2007) 746e751Treatment of hepatic recurrence
Life expectancy of patients with intrahepatic HCC recur-
rence after resection is grim.7 In the present series the
3-year survival rate of patients with recurrence and no treat-
ment was 8%. Our results suggest that an aggressive man-
agement strategy using multiple modalities improve
survival. The best results were observed in patients in
whom re-resection of recurrent HCC could be performed
with 3- and 5-year survivals of 50% and 30%. Three pa-
tients survived for more than 5 years. Re-resection is tech-
nically more demanding than primary resection because of
hypertrophy of the residual liver, modifications in anatom-
ical landmarks and post-operative adhesions. It is particu-
larly troublesome in cirrhotic patients in whom the risk of
bleeding is augmented. However, in the present study, as
in others,6e8,12 resection could be safely performed even
in cirrhotic patients with operative mortality and morbidity
comparable to those of a first resection. It should be noted
that the favourable results of re-resection might partly be
due to a selection of patients with only one or a few recur-
rent nodules and a well preserved liver function.15 There-
fore in this group of patients re-resection should be
considered whenever possible.
Only 19% of all patients with recurrence were suitable for
repeat surgery in the present series. Amongst the remaining
patients, 54 could not receive any treatment because they pre-
sented with multiple disseminated nodules or with a single or
a few nodules but a poor liver function and/or portal vein in-
vasion or an atrophic liver remnant. Twenty-five patients
(26%) with multiple nodules and/or contra indications for
surgery were treated by TACE or PEI. One patient died after
TACE and 12% developed complications associated with the
procedure. Survival was not as good as that following re-
resection but still better than that of patients with conserva-
tive treatment, with a 20.7% 3-year survival. Both treatments
can be combined. Our results suggest that whenever resection
is not indicated, the non-surgical treatment that should be
used is TACE in patients with multifocal recurrence, or local
treatments such as PEI or RF thermal ablation in those with
single recurrent nodules. PEI or RF can be complementary
to surgery.8,27,28 This encourages an aggressive therapeutic
policy, whether surgical or non-surgical, in patients with
HCC recurrence after hepatic resection.
Treatment of extrahepatic recurrence
Treatment of extrahepatic recurrence after resection of
HCC is more controversial, not only because it is less com-
mon than intrahepatic recurrence, but also because a distant
metastasis from HCC is often considered a contraindication
for active treatment. Two of our patients were submitted to
a vertebral body resection of a metastasis of HCC in the spine
with survival of more than 1 year in one. A few previous
reports suggested that resection of an isolated metastasis in
the lung,11,12,14 adrenal gland,30 peritoneal cavity,31 andabdominal wall32 may result in long-term survival in selected
patients. A recent study demonstrated that resection of an iso-
lated extrahepatic recurrence might offer long-term sur-
vival.8 Furthermore, like other studies, our results clearly
show that surgical treatment of recurrence of HCC can be
done safely, just as with the first resection of primary HCC.
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